Skip to main content
Journal cover image

Baseline predictors of A1C reduction in adults using sensor-augmented pump therapy or multiple daily injection therapy: the STAR 3 experience.

Publication ,  Journal Article
Buse, JB; Dailey, G; Ahmann, AA; Bergenstal, RM; Green, JB; Peoples, T; Tanenberg, RJ; Yang, Q
Published in: Diabetes Technol Ther
June 2011

BACKGROUND: Baseline characteristics from the adult cohort of a randomized controlled trial comparing sensor-augmented pump (SAP) and multiple daily injection (MDI) therapy were analyzed for significant relationships with -0.5% A1C change at 1 year of therapy without incidence of severe hypoglycemia (defined as A1C benefit). METHODS: Baseline characteristics were compared with A1C benefit. Statistically significant predictors were analyzed further to determine appropriate cutpoints of relative A1C benefit. RESULTS: Baseline A1C ≥9.1%, age at randomization ≥36 years, and age at diabetes diagnosis of ≥17 years were associated with a greater SAP benefit relative to MDI than other cutpoints. CONCLUSIONS: People with type 1 diabetes who had a high A1C and who were older at diagnosis and older at randomization experienced the most benefit from SAP therapy.

Duke Scholars

Published In

Diabetes Technol Ther

DOI

EISSN

1557-8593

Publication Date

June 2011

Volume

13

Issue

6

Start / End Page

601 / 606

Location

United States

Related Subject Headings

  • Young Adult
  • Treatment Outcome
  • Models, Biological
  • Middle Aged
  • Materials Testing
  • Male
  • Insulin Infusion Systems
  • Insulin
  • Hypoglycemic Agents
  • Hyperglycemia
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Buse, J. B., Dailey, G., Ahmann, A. A., Bergenstal, R. M., Green, J. B., Peoples, T., … Yang, Q. (2011). Baseline predictors of A1C reduction in adults using sensor-augmented pump therapy or multiple daily injection therapy: the STAR 3 experience. Diabetes Technol Ther, 13(6), 601–606. https://doi.org/10.1089/dia.2010.0225
Buse, John B., George Dailey, Andrew A. Ahmann, Richard M. Bergenstal, Jennifer B. Green, Tim Peoples, Robert J. Tanenberg, and Qingqing Yang. “Baseline predictors of A1C reduction in adults using sensor-augmented pump therapy or multiple daily injection therapy: the STAR 3 experience.Diabetes Technol Ther 13, no. 6 (June 2011): 601–6. https://doi.org/10.1089/dia.2010.0225.
Buse JB, Dailey G, Ahmann AA, Bergenstal RM, Green JB, Peoples T, et al. Baseline predictors of A1C reduction in adults using sensor-augmented pump therapy or multiple daily injection therapy: the STAR 3 experience. Diabetes Technol Ther. 2011 Jun;13(6):601–6.
Buse, John B., et al. “Baseline predictors of A1C reduction in adults using sensor-augmented pump therapy or multiple daily injection therapy: the STAR 3 experience.Diabetes Technol Ther, vol. 13, no. 6, June 2011, pp. 601–06. Pubmed, doi:10.1089/dia.2010.0225.
Buse JB, Dailey G, Ahmann AA, Bergenstal RM, Green JB, Peoples T, Tanenberg RJ, Yang Q. Baseline predictors of A1C reduction in adults using sensor-augmented pump therapy or multiple daily injection therapy: the STAR 3 experience. Diabetes Technol Ther. 2011 Jun;13(6):601–606.
Journal cover image

Published In

Diabetes Technol Ther

DOI

EISSN

1557-8593

Publication Date

June 2011

Volume

13

Issue

6

Start / End Page

601 / 606

Location

United States

Related Subject Headings

  • Young Adult
  • Treatment Outcome
  • Models, Biological
  • Middle Aged
  • Materials Testing
  • Male
  • Insulin Infusion Systems
  • Insulin
  • Hypoglycemic Agents
  • Hyperglycemia